| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lana A Del Porto, Simon V Liubinas, Andrew H Kay. Treatment of persistent and recurrent acromegaly. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. vol 18. issue 2. 2011-12-05. PMID:21167718. |
treatment options for acromegaly after failed initial therapy or recurrence include further surgery, radiotherapy, radiosurgery or medical therapies, including somatostatin analogues, dopamine agonists and growth hormone receptor antagonists. |
2011-12-05 |
2023-08-12 |
Not clear |
| S J Neggers, A J van der Lel. Pegvisomant and improvement of quality of life in acromegalic patients. Hormone research in paediatrics. vol 76 Suppl 1. 2011-12-05. PMID:21778759. |
long-acting somatostatin analog (ssa) therapy normalizes serum insulin-like growth factor i (igf-i) levels in approximately 55% of patients, but we postulate that these patients still have acromegaly in many tissues other than the liver. |
2011-12-05 |
2023-08-12 |
Not clear |
| Darja Ciganoka, Inga Balcere, Ivo Kapa, Raitis Peculis, Andra Valtere, Liene Nikitina-Zake, Ieva Lase, Helgi B Schiöth, Valdis Pirags, Janis Klovin. Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly. European journal of endocrinology. vol 165. issue 4. 2011-11-15. PMID:21810856. |
identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly. |
2011-11-15 |
2023-08-12 |
Not clear |
| Darja Ciganoka, Inga Balcere, Ivo Kapa, Raitis Peculis, Andra Valtere, Liene Nikitina-Zake, Ieva Lase, Helgi B Schiöth, Valdis Pirags, Janis Klovin. Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly. European journal of endocrinology. vol 165. issue 4. 2011-11-15. PMID:21810856. |
the aim of this study was to characterize the genetic variance of somatostatin receptor 5 (sstr5) and investigate the possible correlation of such variants with acromegaly risk and different disease characteristics. |
2011-11-15 |
2023-08-12 |
Not clear |
| S J C M M Neggers, A J van der Lel. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 21. issue 3. 2011-10-27. PMID:21498099. |
combination treatment with somatostatin analogues and pegvisomant in acromegaly. |
2011-10-27 |
2023-08-12 |
Not clear |
| S J C M M Neggers, A J van der Lel. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 21. issue 3. 2011-10-27. PMID:21498099. |
mono-therapy using long-acting somatostatin analogues and surgery cannot provide optimal biochemical control in a large proportion of patients with acromegaly. |
2011-10-27 |
2023-08-12 |
Not clear |
| Michael Madsen, Per L Poulsen, Hans Orskov, Niels Møller, Jens O L Jørgense. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. The Journal of clinical endocrinology and metabolism. vol 96. issue 8. 2011-10-14. PMID:21632808. |
cotreatment of acromegaly with pegvisomant and a somatostatin analog (sa) has proven feasible. |
2011-10-14 |
2023-08-12 |
Not clear |
| Sven M Carlsen, Johan Svartberg, Thomas Schreiner, Sylvi Aanderud, Oivind Johannesen, Svein Skeie, Morten Lund-Johansen, Stine L Fougner, Jens Bollersle. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. Clinical endocrinology. vol 74. issue 6. 2011-10-03. PMID:21521254. |
treatment with somatostatin analogues is the primary medical treatment of acromegaly. |
2011-10-03 |
2023-08-12 |
Not clear |
| A Giustina, M D Bronstein, F F Casanueva, P Chanson, E Ghigo, K K Y Ho, A Klibanski, S Lamberts, P Trainer, S Melme. Current management practices for acromegaly: an international survey. Pituitary. vol 14. issue 2. 2011-09-27. PMID:21063787. |
ninety-eight percent of respondents stated that primary treatment with somatostatin receptor ligands (srls) was indicated at least sometime during the management of acromegaly patients. |
2011-09-27 |
2023-08-12 |
Not clear |
| Maria Fleseri. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary. vol 14. issue 2. 2011-09-27. PMID:21161602. |
clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. |
2011-09-27 |
2023-08-12 |
Not clear |
| Maria Fleseri. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary. vol 14. issue 2. 2011-09-27. PMID:21161602. |
somatostatin receptor ligands (srls) are considered the standard medical choice for the treatment of acromegaly, and normalization of gh and igf-1 is attainable with effective therapy. |
2011-09-27 |
2023-08-12 |
Not clear |
| Edward T Maggio, Patricia Grass. Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice. Regulatory peptides. vol 167. issue 2-3. 2011-08-09. PMID:21329733. |
the most effective option for the medical treatment of patients with acromegaly is the use of somatostatin analogs. |
2011-08-09 |
2023-08-12 |
mouse |
| Marcello D Bronstein, Diane B Paraiba, Raquel S Jalla. Management of pituitary tumors in pregnancy. Nature reviews. Endocrinology. vol 7. issue 5. 2011-08-01. PMID:21403665. |
in these patient populations, medical therapy with somatostatin analogues (acromegaly) or drugs that target the adrenal glands, such as metyrapone and ketoconazole (cushing disease), should be reserved for those in whom surgery is unsuccessful or contraindicated. |
2011-08-01 |
2023-08-12 |
Not clear |
| Mark Sherlock, Conor Woods, Michael C Sheppar. Medical therapy in acromegaly. Nature reviews. Endocrinology. vol 7. issue 5. 2011-08-01. PMID:21448141. |
the therapeutic options for acromegaly include surgery, radiotherapy and medical therapies, such as dopamine agonists, somatostatin receptor ligands and the gh receptor antagonist pegvisomant. |
2011-08-01 |
2023-08-12 |
Not clear |
| Annamaria Colao, Renata S Auriemma, Gaetano Lombardi, Rosario Pivonell. Resistance to somatostatin analogs in acromegaly. Endocrine reviews. vol 32. issue 2. 2011-07-21. PMID:21123741. |
resistance to somatostatin analogs in acromegaly. |
2011-07-21 |
2023-08-12 |
Not clear |
| Annamaria Colao, Renata S Auriemma, Gaetano Lombardi, Rosario Pivonell. Resistance to somatostatin analogs in acromegaly. Endocrine reviews. vol 32. issue 2. 2011-07-21. PMID:21123741. |
somatostatin analogs (sa) are widely used in acromegaly, either as first-line or adjuvant treatment after surgery. |
2011-07-21 |
2023-08-12 |
Not clear |
| Nestoras Mathioudakis, Roberto Salvator. Pituitary tumors. Current treatment options in neurology. vol 11. issue 4. 2011-07-14. PMID:19523354. |
somatostatin analogues, such as octreotide and lanreotide, can be adjunctive to surgical therapy in acromegaly, although they can be used as primary therapy in selected cases. |
2011-07-14 |
2023-08-12 |
Not clear |
| Beverly Mk Biller, Annamaria Colao, Stephan Petersenn, Vivien S Bonert, Marco Boscar. Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC endocrine disorders. vol 10. 2011-07-14. PMID:20478050. |
dopamine agonists are an effective first-line medical therapy in most patients with a prolactinoma, and somatostatin analogues can be used as first-line therapy in selected patients with acromegaly. |
2011-07-14 |
2023-08-12 |
Not clear |
| Baldomero González, Guadalupe Vargas, Ana Laura Espinosa-de-los-Monteros, Ernesto Sosa, Moisés Mercad. Efficacy and safety of radiotherapy in acromegaly. Archives of medical research. vol 42. issue 1. 2011-06-20. PMID:21376263. |
transsphenoidal surgery remains the treatment of choice in acromegaly, yet 40-50% of patients require secondary forms of therapy such as radiation therapy (rt) and somatostatin analogues (sa). |
2011-06-20 |
2023-08-12 |
Not clear |
| Miles J Lev. The association of pituitary tumors and headache. Current neurology and neuroscience reports. vol 11. issue 2. 2011-06-03. PMID:21128024. |
the observation that somatostatin analogues can have a dramatic analgesic effect in acromegaly suggests that biochemical properties of the tumor may be important. |
2011-06-03 |
2023-08-12 |
human |